# Pulmotect

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pulmotect

- Industry: Pharmaceuticals
- Headquarters: Houston, US
- Website: www.pulmotect.com
- Total disclosed funding: $16M
- Latest round: Series C (Aug 30, 2024)
- Investors on record: 4

## About

Pulmotect, Inc. is a biopharmaceutical company focused on developing inhaled therapeutics to enhance lung health and combat respiratory infections, particularly for high-risk populations.Founded in 2007 and headquartered in Houston, US, Pulmotect, Inc. specializes in creating unique inhaled therapies. The company has raised USD 10.28 mn in its Series C funding round on August 30, 2024, led by Fannin Innovation Studio with participation from Axil Capital Partners. The firm has completed a total of 4 deals to date.Pulmotect, Inc. specializes in the development of innovative inhaled therapeutics, with a primary focus on its lead product, PUL-042. This first-in-class, patent-protected therapy activates the innate immune system within the lungs, offering immediate protection against various pathogens. PUL-042 is currently in clinical development, having undergone Phase I/2a trials to establish its safety and tolerability among healthy individuals and patients with chronic obstructive pulmonary disease (COPD). The primary target markets include immunocompromised cancer patients, individuals with COPD and asthma, and those at risk for seasonal infections, focusing on expanding into North America and Europe.Pulmotect's revenue strategy relies on the commercialization of its proprietary product, PUL-042, as it advances through clinical trials and regulatory approval. Revenue is expected from partnerships with healthcare providers and institutions, or direct sales to entities managing respiratory disease patient care. The company is developing a pricing strategy that reflects the unique benefits of PUL-042, especially in preventing severe respiratory complications in at-risk populations.In August 2024, Pulmotect, Inc. raised USD 10.28 mn in Series C funding to develop a Phase 2 Anti-Viral trial and to enhance its anti-infective asset. The company plans to extend its product offerings and target expansion into new markets across North America and Europe. This funding will support the ongoing clinical development of PUL-042 and other upcoming products aimed at improving lung health.

## Funding rounds

- Series C, Aug 30, 2024, $10M — Fannin, Axil Capital
- Series B, Mar 23, 2018, $4M — Fannin, Jefferson River Capital
- Series A, Apr 28, 2016, $1.8M — The Houston Angel Network, Fannin

## Investors

- The Houston Angel Network — Series A
- Fannin (https://capitalatlas.ai/funds/fannin) — Series A, Series B, Series C
- Jefferson River Capital — Series B
- Axil Capital (https://capitalatlas.ai/funds/axil-capital) — Series C